An initiative to improve clozapine prescribing in New York state

Jay Carruthers, Marleen Radigan, Matthew D. Erlich, Gyojeong Gu, Rui Wang, Eric Y. Frimpong, Susan M. Essock, Mark Olfson, Enrico G. Castillo, Gregory A. Miller, Lloyd I. Sederer, T. Scott Stroup

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


Clozapine remains the only medication approved for treatmentresistant schizophrenia. But underuse is the norm. In 2010, the New York State Office of Mental Health began a multifaceted initiative to promote the evidence-based use of clozapine. From 2009 to 2013, in the absence of a wellfunded pharmaceutical marketing campaign, the proportion of newclozapine trials among all newoutpatient antipsychotic trials increased 40% among adult New York Medicaid recipients with a diagnosis of schizophrenia. The largest gains occurred in state-operated clinics. New York's experience demonstrates the feasibility of making clozapine more accessible to patients who stand to benefit most.

Original languageEnglish (US)
Pages (from-to)369-371
Number of pages3
JournalPsychiatric Services
Issue number4
StatePublished - Apr 1 2016

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'An initiative to improve clozapine prescribing in New York state'. Together they form a unique fingerprint.

Cite this